
In the same week that Pfizer’s CEO Albert Bourla reiterated China’s growing role in the global pharma industry, the company has ventured to the nation to sign a multi-billion-dollar licensing agreement with Starna Therapeutics focusing on CAR-T therapeutics.
As per the deal, Pfizer is paying $330m upfront to secure ex-China rights to three in vivo CAR-T programmes that are focused on treating autoimmune diseases. Starna is also in line to receive up to $2.3bn in development and commercial milestones, as well as royalties on net sales from any products arising from the partnership.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pfizer remained tight-lipped on the programme specifics, though it confirmed the three are at the “pre-IND” phase. The drugmaker also confirmed it has acquired rights to use the Chinese biotech’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology. Pfizer will be able to exclusively license compounds created under a separate research collaboration and an option to expand the territory to Greater China rights.
Pfizer has previous experience developing ex vivo CAR-T therapies, primarily via licensing agreements with Cellectis and Servier. But the move to bolster its pipeline with in vivo CAR-T candidates echoes a wider industry trend. In vivo is considered more attractive because it removes manufacturing complexities and scalability hurdles.
Eli Lilly has already acquired two in vivo CAR-T developers this year. In February, it spent $2.4bn to take over Orna Therapeutics and then in April outlaid $7bn in its buyout of Kelonia. Johnson & Johnson (J&J) and Moderna have also conducted deals targeting the modality this year.
Pfizer’s chief inflammation and immunology officer Michael Vincent said: “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programmes and technology give us a powerful way to pursue these approaches.”
Earlier this week, Pfizer’s CEO Albert Bourla alluded to China’s growing influence on drug innovation. Speaking at the Jefferies Global Healthcare Conference in London on 17 November, Bourla said that competition is set to move away from the traditional opposition of a Western big pharma company amid China’s significant growth in recent years.
While traditional licensing deals – like Pfizer and Starna’s – are still being conducted, an increased focus on national security policies in the US means other types of transactions could be curtailed.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
